Labelling of <svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.06579971pt" id="M1" height="15.3182pt" version="1.1" viewBox="-0.0657574 -15.2524 13.0148 15.3182" width="13.0148pt"><g transform="matrix(.012,0,0,-0.012,0,-7.578)"><path id="g22-55" d="M257 635C101 635 25 509 25 419C25 312 99 229 220 229C237 229 254 234 278 246L328 272C302 155 197 53 48 27L55 -15C99 -14 188 2 228 18C369 73 478 199 478 382C478 518 403 635 257 635ZM236 589C313 589 339 482 339 386C339 366 338 342 334 315C320 309 304 303 279 303C206 303 159 375 159 459C159 522 183 589 236 589Z"/></g><g transform="matrix(.012,0,0,-0.012,6.09,-7.578)"><path id="g22-46" d="M255 635C86 635 29 459 29 311C29 167 83 -12 254 -12S478 166 478 312C478 457 425 635 255 635ZM252 588C317 588 338 455 338 314C338 176 322 35 256 35C191 35 169 183 169 315C169 448 185 588 252 588Z"/></g></svg>Y- and <svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.06579971pt" id="M2" height="15.3182pt" version="1.1" viewBox="-0.0657574 -15.2524 19.1277 15.3182" width="19.1277pt"><g transform="matrix(.012,0,0,-0.012,0,-7.578)"><path id="g22-47" d="M415 0V41C335 46 327 62 327 127V635C236 611 161 593 93 583V547L150 544C187 541 192 535 192 483V127C192 59 182 46 102 41V0H415Z"/></g><g transform="matrix(.012,0,0,-0.012,6.09,-7.578)"><path id="g22-53" d="M482 623L67 622C60 580 54 527 40 445H81C108 505 116 513 184 513H391C306 352 206 176 87 2L95 -12L203 0C294 205 397 410 492 611L482 623Z"/></g><g transform="matrix(.012,0,0,-0.012,12.18,-7.578)"><use xlink:href="#g22-53"/></g></svg>Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis

<div>Comparison of the performances of three different approaches preparing <sup>90</sup>Y- and <sup>177</sup>Lu-DOTATOC. The precursor/radionuclide ratio was 13 ng/MBq for yttrium-90 and 11 ng/MBq for lutetium-177, respectively.</div>

Contrast Media & Molecular Imaging

fig5

Figure 5

Figure 5: Labelling of <svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.06579971pt" id="M1" height="15.3182pt" version="1.1" viewBox="-0.0657574 -15.2524 13.0148 15.3182" width="13.0148pt"><g transform="matrix(.012,0,0,-0.012,0,-7.578)"><path id="g22-55" d="M257 635C101 635 25 509 25 419C25 312 99 229 220 229C237 229 254 234 278 246L328 272C302 155 197 53 48 27L55 -15C99 -14 188 2 228 18C369 73 478 199 478 382C478 518 403 635 257 635ZM236 589C313 589 339 482 339 386C339 366 338 342 334 315C320 309 304 303 279 303C206 303 159 375 159 459C159 522 183 589 236 589Z"/></g><g transform="matrix(.012,0,0,-0.012,6.09,-7.578)"><path id="g22-46" d="M255 635C86 635 29 459 29 311C29 167 83 -12 254 -12S478 166 478 312C478 457 425 635 255 635ZM252 588C317 588 338 455 338 314C338 176 322 35 256 35C191 35 169 183 169 315C169 448 185 588 252 588Z"/></g></svg>Y- and <svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.06579971pt" id="M2" height="15.3182pt" version="1.1" viewBox="-0.0657574 -15.2524 19.1277 15.3182" width="19.1277pt"><g transform="matrix(.012,0,0,-0.012,0,-7.578)"><path id="g22-47" d="M415 0V41C335 46 327 62 327 127V635C236 611 161 593 93 583V547L150 544C187 541 192 535 192 483V127C192 59 182 46 102 41V0H415Z"/></g><g transform="matrix(.012,0,0,-0.012,6.09,-7.578)"><path id="g22-53" d="M482 623L67 622C60 580 54 527 40 445H81C108 505 116 513 184 513H391C306 352 206 176 87 2L95 -12L203 0C294 205 397 410 492 611L482 623Z"/></g><g transform="matrix(.012,0,0,-0.012,12.18,-7.578)"><use xlink:href="#g22-53"/></g></svg>Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis 

Figure 5 | Labelling of Y- and Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison among Manual, Semiautomated, and Fully Automated Synthesis 